Codexis, Inc., a leading provider of enzymatic solutions for efficient and scalable therapeutic manufacturing, and Nitto Denko Avecia, Inc., a prominent contract development and manufacturing organisation (CDMO) specialising in oligonucleotide therapeutics, have announced an evaluation agreement aimed at advancing next-generation oligonucleotide production technologies.

Under the agreement, Nitto Denko Avecia will evaluate Codexis’ ECO Synthesis™ Manufacturing Platform, an enzyme-catalysed alternative to traditional solid-phase oligonucleotide synthesis. The collaboration is expected to pave the way for potential licensing discussions and support the broader adoption of enzyme-driven synthesis methods designed for scalability and sustainability.The partnership combines Codexis’ enzymatic innovation with Nitto Denko Avecia’s large-scale manufacturing expertise, representing a key step toward advancing sustainable and efficient siRNA therapeutic production.

Codexis continues to redefine therapeutic manufacturing by leading the enzymatic technology revolution, providing efficient, high-quality, and commercially proven solutions that outperform traditional methods.

Nitto Denko Avecia operates state-of-the-art facilities in Milford, Massachusetts, and Cincinnati, Ohio, offering comprehensive oligonucleotide development and manufacturing services from preclinical to commercial scale.